Cases & Deals

  • Home
  • Practices
  • Celgene successfully blocks institution of inter partes review on three patents listed in the Orange Book for its blockbuster REVLIMID® product

Share

Celgene successfully blocks institution of inter partes review on three patents listed in the Orange Book for its blockbuster REVLIMID® product

February 2019

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in successfully blocking institution of inter partes review ("IPR") of three patents covering the use of Celgene's REVLIMID® brand drug to treat myelodysplastic syndrome (“MDS”). Following Celgene's filing of its Patent Owner Preliminary Response to each petition, the Patent Trial and Appeal Board ("PTAB") denied institution of inter partes review for all three patents, finding that Dr. Reddy’s Laboratories, Inc. had not shown a reasonable likelihood of prevailing in its unpatentability challenges.

Dr. Reddy's Laboratories, Inc. v. Celgene Corp., IPR Nos. 2018-01504, -01507, -01509 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.